Cardiac Resynchronization Therapy Crt — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cardiac Resynchronization Therapy (CRT) is a specialised pacemaker-based treatment for heart failure caused or worsened by electrical dyssynchrony — a condition in which the left and right ventricles contract in an uncoordinated fashion due to delays in the heart's conduction system, most commonly left bundle branch block (LBBB). This mechanical dyssynchrony reduces the efficiency of cardiac contraction and contributes significantly to the symptoms and progression of heart failure.

CRT works by delivering precisely timed electrical stimulation to both the right ventricle and the left ventricle simultaneously (biventricular pacing), restoring coordinated contraction of the two ventricles and improving the overall mechanical efficiency of the heart. The device consists of a pulse generator implanted in the left pectoral region (chest wall), connected via three leads: one positioned in the right atrium to sense atrial activity, one in the right ventricle, and a third threaded through the coronary sinus and positioned in a lateral or posterolateral branch of the left ventricular surface (epicardial pacing).

CRT is available in two forms: CRT-P (pacemaker only, also called biventricular pacemaker) for patients who do not have an indication for defibrillator therapy, and CRT-D (combined resynchronisation therapy and implantable cardioverter-defibrillator) for patients who are also at high risk of sudden cardiac death. The majority of CRT patients in clinical practice receive CRT-D, given that most have severely reduced left ventricular function, which itself represents an indication for ICD therapy. The implant procedure is performed in a cardiac electrophysiology or cardiac surgery suite under local anaesthesia with sedation, typically lasting 2–4 hours.

CRT is principally indicated for patients with symptomatic heart failure (NYHA class II–IV) with severe left ventricular dysfunction (LVEF 35% or below) who remain symptomatic despite optimal medical therapy (ACE inhibitor/ARNi, beta-blocker, mineralocorticoid receptor antagonist, SGLT2 inhibitor) and have a wide QRS complex (QRS duration 130 milliseconds or greater on ECG), particularly LBBB morphology. LBBB is associated with the greatest electrical dyssynchrony and predicts the largest benefit from CRT, while right bundle branch block (RBBB) and non-specific intraventricular conduction delay show variable responses.

Heart failure with reduced ejection fraction (HFrEF) is the primary indication, encompassing both ischaemic cardiomyopathy (following myocardial infarction) and non-ischaemic dilated cardiomyopathy. CRT may also be considered in patients with high-degree AV block requiring pacing who have reduced LVEF, to avoid pacemaker-induced dyssynchrony from right ventricular pacing alone (upgrade from standard pacemaker to CRT). Patients with mildly symptomatic heart failure (NYHA class II) with LBBB and QRS above 150 ms derive benefit from CRT, as demonstrated in the MADIT-CRT and REVERSE trials.

Ideal CRT candidates are patients with LVEF of 35% or less, NYHA class II–III symptoms (occasionally class IV ambulatory), QRS duration of 130 ms or greater (with the greatest benefit at QRS 150 ms or greater, especially LBBB morphology), sinus rhythm (though CRT in AF has evidence of benefit in selected patients), and life expectancy exceeding 1 year with good functional status in a non-cardiac domain. Pre-implant cardiac MRI or echocardiography assesses mechanical dyssynchrony and viable myocardium — patients with extensive scar at the intended left ventricular pacing site have limited CRT response.

Non-responders to CRT (approximately 30–40% of implanted patients who do not show significant improvement) are more likely to have RBBB morphology, non-LBBB, narrow QRS (below 130 ms), extensive left ventricular scar, suboptimal lead placement, or inadequate device programming. Patients with ischaemic cardiomyopathy tend to have slightly lower response rates than those with non-ischaemic dilated cardiomyopathy. The absence of viable myocardium at the proposed left ventricular pacing site — identified by MRI viability imaging or nuclear perfusion — predicts poor response and may guide alternative approaches.

Standard CRT uses transvenous coronary sinus lead placement for left ventricular pacing. The left ventricular lead is advanced through the coronary sinus and positioned in a lateral or anterolateral branch, ideally at the site of latest mechanical activation identified by echocardiography or cardiac MRI, and away from regions of dense scar. Technical challenges include failure to cannulate the coronary sinus in 5–10% of cases, inadequate lateral or posterolateral branch anatomy, and high pacing thresholds or phrenic nerve stimulation at optimal anatomical sites.

When transvenous CRT lead placement fails or is not feasible, surgical epicardial left ventricular lead placement via limited thoracotomy provides an alternative route. Conduction system pacing — His bundle or left bundle branch area (LBBA) pacing — is an emerging alternative that engages the native conduction system to achieve physiological biventricular activation without a coronary sinus lead, and is particularly valuable for patients with unsuitable coronary sinus anatomy or CRT non-responders to standard biventricular pacing. Multi-point pacing, in which two electrodes on the same LV lead deliver sequential stimulation, broadens the activation wave front and may improve response rates in patients with extensive scar. Extravascular ICD (EV-ICD) technology, delivering shocks from an intravascular lead positioned outside the cardiac chambers, broadens the activation wave front and may improve response rates in patients with extensive scar. The SMART-AV and RESPOND CRT trials have refined optimal AV and VV delay programming strategies to maximise haemodynamic benefit and clinical response.

CRT is one of the most rigorously evidenced device therapies in cardiology, with benefits demonstrated across multiple large randomised controlled trials. The CARE-HF and COMPANION trials established that CRT reduces all-cause mortality by 24–36% and hospitalisations for heart failure by 34–52% compared to optimal medical therapy alone in appropriate patients. LVEF typically improves by an average of 10–15 percentage points within 3–6 months of CRT implantation — an improvement reflecting genuine reverse remodelling of the failing ventricle.

Symptomatic improvement occurs in 60–70% of patients (defined as an improvement of at least one NYHA class), with many patients experiencing dramatic functional improvements — resuming activities they had abandoned due to breathlessness and fatigue. Left ventricular end-systolic volume decreases by an average of 15–25%, reflecting reduction in adverse remodelling. Quality-of-life measures (Minnesota Living with Heart Failure questionnaire) improve significantly. In the MADIT-CRT trial, CRT-D compared to ICD alone in NYHA class I–II patients with LBBB reduced the primary composite endpoint of heart failure events or death by 41%.

CRT implantation carries the general risks of pacemaker and ICD implantation plus specific complications related to the coronary sinus lead. Left ventricular lead displacement occurs in 5–10% of cases within the first 3 months and may require repositioning. Phrenic nerve stimulation — causing diaphragmatic pacing and unpleasant twitching sensations — occurs in 2–5% of patients and is managed by lead repositioning, programming changes, or rarely surgical revision. Coronary sinus dissection or perforation during lead advancement is rare (0.3–0.5%) but may require pericardiocentesis.

CRT non-response (defined as failure to improve by at least one NYHA class and failure of reverse remodelling) affects 30–40% of patients. Careful patient selection, optimal lead placement guided by echocardiographic or imaging-based dyssynchrony assessment, and thorough post-implant programming optimisation (AV delay, VV delay) improve responder rates. ICD-related risks for CRT-D patients include inappropriate shocks (10–15% annually) and device pocket infection. Total system extraction — required for lead failure or device infection — is a higher-risk procedure when a coronary sinus lead is included in the system.

Patients are hospitalised for 1–2 days following CRT implantation. An immediate post-procedure chest X-ray confirms lead positions and excludes pneumothorax. Restriction of arm movement on the implant side for 4–6 weeks allows lead fixation. Device clinic review at 6 weeks optimises device programming — particularly AV delay (to maximise left ventricular filling time) and VV timing (the interval between right and left ventricular stimulation, optimised by echocardiography for maximum haemodynamic benefit).

Serial echocardiography at 3, 6, and 12 months assesses reverse remodelling — improvement in LVEF, reduction in LV volumes, and mitral regurgitation reduction. Heart failure medical therapy is continued and optimised in parallel; CRT is complementary to rather than a substitute for guideline-directed pharmacological therapy. Long-term device follow-up (every 6–12 months or via remote monitoring for modern devices) tracks lead parameters, battery longevity, arrhythmia burden, and CRT pacing percentage — ideally above 98% biventricular pacing. Patients not responding to CRT require reassessment of device programming, lead position, and consideration of conduction system pacing upgrade.

CRT-D device implantation in the United States costs between $60,000 and $120,000, encompassing the device generator, three leads, implantation procedure, and hospital stay. CRT-P (without defibrillator) costs $40,000–$70,000. Medicare covers CRT implantation for eligible patients meeting guideline criteria; however, deductibles and co-payments apply. In the UK, NHS implantation of CRT is provided free of charge for eligible patients, with private costs ranging from £18,000 to £35,000.

For international patients, CRT-D and CRT-P implantation at JCI-accredited Indian cardiac centres (Fortis Escorts, Apollo, Medanta) costs approximately $12,000–$25,000 for CRT-D and $8,000–$15,000 for CRT-P, including device, procedure, and hospital stay — savings of 70–80% versus US costs. The CRT devices used at leading Indian centres are identical internationally approved devices (Medtronic, Abbott, Boston Scientific, Biotronik), and Indian electrophysiologists performing CRT implantation have equivalent training and procedural volumes to their Western counterparts. Thailand and Turkey offer intermediate pricing of $20,000–$40,000 for CRT-D.

Optimisation of guideline-directed medical therapy (GDMT) — maximally tolerated doses of ACE inhibitor or sacubitril-valsartan (ARNI), beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor — is the foundation of heart failure management and should be maximised before CRT implantation, though CRT is indicated when patients remain symptomatic despite GDMT. Sacubitril-valsartan has demonstrated 20% relative risk reduction in cardiovascular mortality and heart failure hospitalisation versus enalapril (PARADIGM-HF trial) and should be used as the first-line renin-angiotensin system blocker in symptomatic HFrEF before consideration of CRT.

For patients failing CRT who have severely advanced heart failure, left ventricular assist device (LVAD) therapy — either as a bridge to cardiac transplantation or as destination therapy — provides mechanical circulatory support that dramatically improves survival and quality of life in refractory HFrEF. Cardiac transplantation remains the gold standard for end-stage heart failure in appropriate candidates, offering superior outcomes to all medical and device therapies. Conduction system pacing (His or LBBA pacing) is an emerging alternative to biventricular CRT that may achieve equivalent resynchronisation while avoiding some coronary sinus lead complications.